Infant Bacterial Therapeutics AB (publ)

OM:IBT B 주식 보고서

시가총액: SEK 514.6m

Infant Bacterial Therapeutics 관리

관리 기준 확인 2/4

Infant Bacterial Therapeutics CEO는 Staffan Stromberg, Jan2013 에 임명되었습니다 의 임기는 11.83 년입니다. 총 연간 보상은 SEK 5.33M, 57.9% 로 구성됩니다. 57.9% 급여 및 42.1% 보너스(회사 주식 및 옵션 포함). 는 SEK 4.08M 가치에 해당하는 회사 주식의 0.79% 직접 소유합니다. 4.08M. 경영진과 이사회의 평균 재임 기간은 각각 1.5 년과 7.5 년입니다.

주요 정보

Staffan Stromberg

최고 경영자

SEK 5.3m

총 보상

CEO 급여 비율57.9%
CEO 임기11.8yrs
CEO 소유권0.8%
경영진 평균 재임 기간1.5yrs
이사회 평균 재임 기간7.5yrs

최근 관리 업데이트

Infant Bacterial Therapeutics AB (publ)'s (STO:IBT B) CEO Compensation Is Looking A Bit Stretched At The Moment

May 02
Infant Bacterial Therapeutics AB (publ)'s (STO:IBT B) CEO Compensation Is Looking A Bit Stretched At The Moment

Recent updates

We Think Infant Bacterial Therapeutics (STO:IBT B) Can Afford To Drive Business Growth

Aug 02
We Think Infant Bacterial Therapeutics (STO:IBT B) Can Afford To Drive Business Growth

Infant Bacterial Therapeutics AB (publ)'s (STO:IBT B) CEO Compensation Is Looking A Bit Stretched At The Moment

May 02
Infant Bacterial Therapeutics AB (publ)'s (STO:IBT B) CEO Compensation Is Looking A Bit Stretched At The Moment

Infant Bacterial Therapeutics (STO:IBT B) Is In A Good Position To Deliver On Growth Plans

Apr 03
Infant Bacterial Therapeutics (STO:IBT B) Is In A Good Position To Deliver On Growth Plans

Here's Why We're Not Too Worried About Infant Bacterial Therapeutics' (STO:IBT B) Cash Burn Situation

Sep 16
Here's Why We're Not Too Worried About Infant Bacterial Therapeutics' (STO:IBT B) Cash Burn Situation

We Think Infant Bacterial Therapeutics (STO:IBT B) Can Afford To Drive Business Growth

May 11
We Think Infant Bacterial Therapeutics (STO:IBT B) Can Afford To Drive Business Growth

We're Not Very Worried About Infant Bacterial Therapeutics' (STO:IBT B) Cash Burn Rate

Sep 23
We're Not Very Worried About Infant Bacterial Therapeutics' (STO:IBT B) Cash Burn Rate

We're Hopeful That Infant Bacterial Therapeutics (STO:IBT B) Will Use Its Cash Wisely

Apr 07
We're Hopeful That Infant Bacterial Therapeutics (STO:IBT B) Will Use Its Cash Wisely

We Think Infant Bacterial Therapeutics (STO:IBT B) Can Afford To Drive Business Growth

Dec 15
We Think Infant Bacterial Therapeutics (STO:IBT B) Can Afford To Drive Business Growth

We Think Infant Bacterial Therapeutics (STO:IBT B) Can Afford To Drive Business Growth

Aug 25
We Think Infant Bacterial Therapeutics (STO:IBT B) Can Afford To Drive Business Growth

We're Not Very Worried About Infant Bacterial Therapeutics' (STO:IBT B) Cash Burn Rate

May 06
We're Not Very Worried About Infant Bacterial Therapeutics' (STO:IBT B) Cash Burn Rate

Anthon Jahreskog Just Bought A Sprinkling of Shares In Infant Bacterial Therapeutics AB (publ) (STO:IBT B)

Feb 07
Anthon Jahreskog Just Bought A Sprinkling of Shares In Infant Bacterial Therapeutics AB (publ) (STO:IBT B)

CEO 보상 분석

Staffan Stromberg 의 보수는 Infant Bacterial Therapeutics 의 수익과 비교하여 어떻게 변경되었나요?
날짜총 보상급여회사 수익
Sep 30 2024n/an/a

-SEK 144m

Jun 30 2024n/an/a

-SEK 142m

Mar 31 2024n/an/a

-SEK 128m

Dec 31 2023SEK 5mSEK 3m

-SEK 123m

Sep 30 2023n/an/a

-SEK 122m

Jun 30 2023n/an/a

-SEK 99m

Mar 31 2023n/an/a

-SEK 69m

Dec 31 2022SEK 6mSEK 3m

-SEK 65m

Sep 30 2022n/an/a

-SEK 42m

Jun 30 2022n/an/a

-SEK 34m

Mar 31 2022n/an/a

-SEK 65m

Dec 31 2021SEK 5mSEK 3m

-SEK 45m

Sep 30 2021n/an/a

-SEK 55m

Jun 30 2021n/an/a

-SEK 74m

Mar 31 2021n/an/a

-SEK 73m

Dec 31 2020SEK 4mSEK 2m

-SEK 72m

Sep 30 2020n/an/a

-SEK 73m

Jun 30 2020n/an/a

-SEK 65m

Mar 31 2020n/an/a

-SEK 44m

Dec 31 2019SEK 3mSEK 2m

-SEK 46m

Sep 30 2019n/an/a

-SEK 43m

Jun 30 2019n/an/a

-SEK 40m

Mar 31 2019n/an/a

-SEK 32m

Dec 31 2018SEK 3mSEK 2m

-SEK 41m

Sep 30 2018n/an/a

-SEK 26m

Jun 30 2018n/an/a

-SEK 22m

Mar 31 2018n/an/a

-SEK 37m

Dec 31 2017SEK 3mSEK 1m

-SEK 36m

보상 대 시장: Staffan 의 총 보상 ($USD 482.38K )은 Swedish 시장( $USD 235.48K ).

보상과 수익: Staffan 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.


CEO

Staffan Stromberg (57 yo)

11.8yrs

테뉴어

SEK 5,327,000

보상

Mr. Staffan Stromberg, Ph.D. Eng has been the Chief Executive Officer at Infant Bacterial Therapeutics AB (publ) since 2013. Mr. Stromberg served as Director at Genetic Analysis AS since October 28, 2020 u...


리더십 팀

이름위치테뉴어보상소유권
Staffan Stromberg
Chief Executive Officer11.8yrsSEK 5.33m0.79%
SEK 4.1m
Maria Ekdahl
Chief Financial Officer2.2yrs데이터 없음0.035%
SEK 179.8k
Anders Kronström
Chief Operating Officer6.8yrsSEK 500.00k0.083%
SEK 427.6k
Thomas Schnitzer
Chief Scientific Officerless than a year데이터 없음데이터 없음
Sanjiv Sharma
Head of Medical Affairsless than a year데이터 없음데이터 없음
Jonas Rastad
Chief Medical Officerless than a year데이터 없음데이터 없음

1.5yrs

평균 재임 기간

57yo

평균 연령

경험이 풍부한 관리: IBT B 의 관리팀은 경험 (평균 재직 기간 1.5 년)으로 간주되지 않으므로 새로운 팀을 추천합니다.


이사회 구성원

이름위치테뉴어보상소유권
Peter Rothschild
Chairman13.8yrsSEK 727.00k데이터 없음
Margareta Hagman
Independent Director9.2yrsSEK 153.00k0.039%
SEK 201.8k
Eva Idén
Independent Director7.5yrsSEK 153.00k0.0042%
SEK 21.4k
Kristina Nygren
Independent Director6.5yrsSEK 153.00k0.00074%
SEK 3.8k
Anthon Jahreskog
Independent Director7.5yrsSEK 193.00k0.18%
SEK 927.1k

7.5yrs

평균 재임 기간

58yo

평균 연령

경험이 풍부한 이사회: IBT B 의 이사회경험(평균 재직 기간 7.5 년)으로 간주됩니다.